1. Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005;46:1042–51.
2. Albright L, Seab JA, Ommaya AK, et al. Intracerebral delayed hypersensitivity reactions in glioblastoma multiforme patients. Cancer 1977;39:1331–6.
3. Allen J, Packer R, Bleyer A, et al. Recombinant interferon beta: a phase I–II trial in children with recurrent brain tumors. J Clin Oncol 1991;9:783–8.
4. Aoki T, Takahashi JA, Ueba T, et al. Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 2006;105:385–91.
5. Barba D, Saris S, Holder C, et al. Intramural LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175–82.